GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Agilon Health Inc (NYSE:AGL) » Definitions » ROE %

Agilon Health (Agilon Health) ROE % : -120.16% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Agilon Health ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Agilon Health's annualized net income for the quarter that ended in Dec. 2023 was $-922 Mil. Agilon Health's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $767 Mil. Therefore, Agilon Health's annualized ROE % for the quarter that ended in Dec. 2023 was -120.16%.

The historical rank and industry rank for Agilon Health's ROE % or its related term are showing as below:

AGL' s ROE % Range Over the Past 10 Years
Min: -100.72   Med: -30.84   Max: -9.99
Current: -28.93

During the past 5 years, Agilon Health's highest ROE % was -9.99%. The lowest was -100.72%. And the median was -30.84%.

AGL's ROE % is ranked worse than
80.49% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: 4.115 vs AGL: -28.93

Agilon Health ROE % Historical Data

The historical data trend for Agilon Health's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agilon Health ROE % Chart

Agilon Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - -100.72 -9.99 -30.84

Agilon Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.24 6.04 -6.83 -14.35 -120.16

Competitive Comparison of Agilon Health's ROE %

For the Medical Care Facilities subindustry, Agilon Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agilon Health's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Agilon Health's ROE % distribution charts can be found below:

* The bar in red indicates where Agilon Health's ROE % falls into.



Agilon Health ROE % Calculation

Agilon Health's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-262.596/( (1041.22+661.839)/ 2 )
=-262.596/851.5295
=-30.84 %

Agilon Health's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-921.732/( (872.367+661.839)/ 2 )
=-921.732/767.103
=-120.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Agilon Health  (NYSE:AGL) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-921.732/767.103
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-921.732 / 3262.016)*(3262.016 / 2009.4705)*(2009.4705 / 767.103)
=Net Margin %*Asset Turnover*Equity Multiplier
=-28.26 %*1.6233*2.6196
=ROA %*Equity Multiplier
=-45.87 %*2.6196
=-120.16 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-921.732/767.103
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-921.732 / -650.668) * (-650.668 / -638.408) * (-638.408 / 3262.016) * (3262.016 / 2009.4705) * (2009.4705 / 767.103)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.4166 * 1.0192 * -19.57 % * 1.6233 * 2.6196
=-120.16 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Agilon Health ROE % Related Terms

Thank you for viewing the detailed overview of Agilon Health's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Agilon Health (Agilon Health) Business Description

Traded in Other Exchanges
N/A
Address
6210 E. US Highway 290, Suite 450, Austin, TX, USA, 78723
Agilon Health Inc is transforming healthcare by empowering community-based physicians with the resources and expertise they need to innovate the payment and delivery of care for seniors. The company enables physicians to create their own Medicare-centric globally capitated line of business.
Executives
Jeffrey A. Schwaneke director C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
Steven Sell director, officer: CEO & President C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
Benjamin Shaker officer: Chief Markets Officer C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
Timothy Gertsch officer: Chief Accounting Officer C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
Silvana Battaglia director 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Cd&r Investment Associates Ix, Ltd. 10 percent owner MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, GRAND CAYMAN E9 KY101194
Veeral Desai officer: Chief Strategy & Dev. Officer C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
Benjamin Kornitzer officer: Chief Med. & Quality Officer C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
John William Wulf director C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
Diana Mckenzie director METLIFE, 200 PARK AVENUE, NEW YORK NY 10166
Priscilla Kasenchak officer: Chief Accounting Officer 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Michael L Smith director C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
Theodore Halkias officer: Chief Business Officer C/O AGILON HEALTH, INC., 1 WORLD TRADE CENTER, SUITE 2000, LONG BEACH CA 90831
Joan Danieley officer: Chief Administrative Officer C/O AGILON HEALTH, INC., 1 WORLD TRADE CENTER, SUITE 2000, LONG BEACH CA 90831
Glenn Sobotka officer: Chief Accounting Officer C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723